Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
市場動向レポート 無料ダウンロード
Orphan Drugs 2023-2028: A flattening curve?
300 million people around the world live with a rare disease. This perhaps explains the seemingly endless growth of orphan drugs and the forecasted $300bn market by 2028. Is this growth set to continue? Well, in the short term, yes. Longer term? Perhaps not. However, between now and 2028, Evaluate Pharma forecasts growth of close to 12%…
レポートライブラリ
Orphan Drugs: Ready to Peak?
What’s the big deal about orphan drugs? Well, they form the fastest-growing segment of the pharma market and dominate FDA approvals for a start. The diseases they treat…
Orphan Drug 2023-2023: Is the shine coming off?
After a decade of outpacing the market, are we finally going to see a plateau in the growth of orphan drugs? Well, maybe. Data-wise, there’s only a hint of that being the…
PD(L)anner – February 2023
The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in…
Cardiology: the heart of the matter
This infographic gives you the vital signs of the cardiology landscape. Get a snapshot of the key medtech approvals, the industry players that are driving cardiology…
Biopharma and Medtech Review 2022
To even the most optimistic soul, 2022 was not a vintage year for the world of biopharma and medtech. Public markets continued their downward trajectory and many…
Obesity matters for drug developers
Close to 40% of the US adult population is now obese and the WHO and AMA define obesity as a disease. So it’s perhaps no surprise that Evaluate Pharma is forecasting…
Five questions to ask when reviewing your pipeline
Pharma’s R&D pipeline is its lifeblood. The industry-wide pipeline is today worth a staggering $1.4 trillion. Yet, like many others, you may find that getting R&D…
JP Morgan Healthcare Conference 2023
The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started…
Evaluate Vantage 2023 Preview Infographic
The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already…
ASH 2022
As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering…
